+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Muscle Relaxant Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Route of Administration (Oral and Injectable), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2029

  • PDF Icon

    Report

  • 194 Pages
  • May 2023
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5833630
Description Jump to:
The Global Muscle Relaxant Drugs Market size is expected to reach $4.7 billion by 2029, rising at a market growth of 4.3% CAGR during the forecast period.

Neuromuscular Blocking Agents are significantly capturing the market because of the increasing prevalence of skin diseases and damaging effects of ultraviolet radiation, the rising disposable income leading to increased expenditures on facial aesthetics therapy, and the rising use of neuromuscular blocking agents in surgical procedures. Thus, Neuromuscular Blocking Agents is expected to generate more than 37% share by 2029. More than 882 million individuals in 44 countries remain at risk for lymphatic filariasis in 2021, and preventative treatment is needed to halt the development of this parasitic ailment. 51 million individuals were sick as of 2018 - a 74% decrease since the Global Programme to Eliminate Lymphatic Filariasis of the WHO began in 2000. Some of the factors impacting the market are the increase in Musculoskeletal Conditions, the increasing number of senior citizens, and adverse muscle relaxant side effects.



The most prevalent type of non-cancer pain is discomfort felt in musculoskeletal structures. According to the WHO, 1.71 billion people globally have musculoskeletal disorders, including rheumatoid arthritis, osteoarthritis, amputation, low back pain, neck discomfort, fractures, and other injuries. According to WHO, by 2030, one in six people will be 60 or elderly. There will be 1.4 billion individuals over 60, up from 1 billion in 2020. By 2050, the global population of individuals aged 60 and elderly will have doubled to 2.1 billion. In addition, the number of individuals aged 80 or older is projected to triple between 2020 and 2050, reaching 426 million. Due to the high need for demyelinating disease treatments among this population, the market has considerable growth potential.

However, patients with a history of liver disease, seizures, and other medical conditions or issues are at an increased risk for adverse effects. In addition, pregnant women who intend to become pregnant or are breastfeeding require special attention. As total body relaxants, muscle relaxants typically induce drowsiness or grogginess. As a result, it is unsafe to operate a vehicle or make vital decisions while under the influence of muscle relaxants.

Drug Type Outlook

Based on drug type, the market is segmented into skeletal, facial muscle relaxant drugs and neuromuscular blocking agents. The skeletal segment dominated the market with maximum revenue share in 2022. This is because skeletal muscle relaxants were initially approved to treat muscle spasms and back pain temporarily. Now, they are commonly used to treat chronic pain as well as a variety of other conditions. In addition, people seek medical assistance for a variety of reasons, but the most common one is pain. Thus, their use for the treatment of chronic pain and muscle spasms is expected to propel the segment's growth.



Route of Administration Outlook

On the basis of route of administration, the market is divided into oral and injectable. The injectable segment procured a substantial revenue share in the market in 2022. This is due to the fact that the most important companies in the market are working on the creation of innovative new items. Before undergoing general anesthesia, this muscle relaxant is given to the patient. Also, one of the most well-known applications of muscle relaxant injections in anti-aging medication is to reduce the appearance of wrinkles and lines on the forehead and the eyelids, which aids in the segment's growth.

Distribution Channel Outlook

By distribution channel, the market is classified into hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacy segment witnessed the largest revenue share in the market in 2022. This is owing to the expanding awareness and an increase in clinical and hospital visits. In addition, the increasing geriatric population is a significant factor propelling the segment's expansion. This is due to the fact that the elderly are frequently hospitalized for a variety of chronic disorders for which they receive such medications. Thus, the segment is expected to propel due to the growing hospital admissions and the rising geriatric population.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the market in 2022. The growth is attributed to increased government investment, a rise in the incidence of chronic diseases, and the region's high-quality infrastructure. Due to the increasing number of surgical procedures and high disposable income, the market is expected to grow. Also, the presence of a large elderly population in this region contributes to the high prevalence of chronic back pain and further surge the market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.

Scope of the Study

By Drug Type

  • Skeletal
  • Neuromuscular Blocking Agents
  • Facial Muscle Relaxant Drugs

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Amneal Pharmaceuticals, Inc.
  • Ipsen Pharma Biotech SAS
  • Merz Pharma GmbH & Co. KGaA
  • Mallinckrodt PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Eisai Co., Ltd.
  • Endo International PLC
  • Vertical Pharmaceuticals, LLC
  • SteriMax Inc.
  • Metacel Pharmaceuticals, LLC

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Muscle Relaxant Drugs Market, by Drug Type
1.4.2 Global Muscle Relaxant Drugs Market, by Route of Administration
1.4.3 Global Muscle Relaxant Drugs Market, by Distribution Channel
1.4.4 Global Muscle Relaxant Drugs Market, by Geography
1.5 Research Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Muscle Relaxant Drugs Market by Drug Type
3.1 Global Skeletal Market by Region
3.2 Global Neuromuscular Blocking Agents Market by Region
3.3 Global Facial Muscle Relaxant Drugs Market by Region
Chapter 4. Global Muscle Relaxant Drugs Market by Route of Administration
4.1 Global Oral Market by Region
4.2 Global Injectable Market by Region
Chapter 5. Global Muscle Relaxant Drugs Market by Distribution Channel
5.1 Global Hospital Pharmacy Market by Region
5.2 Global Retail Pharmacy Market by Region
5.3 Global Online Pharmacies Market by Region
Chapter 6. Global Muscle Relaxant Drugs Market by Region
6.1 North America Muscle Relaxant Drugs Market
6.1.1 North America Muscle Relaxant Drugs Market by Drug Type
6.1.1.1 North America Skeletal Market by Country
6.1.1.2 North America Neuromuscular Blocking Agents Market by Country
6.1.1.3 North America Facial Muscle Relaxant Drugs Market by Country
6.1.2 North America Muscle Relaxant Drugs Market by Route of Administration
6.1.2.1 North America Oral Market by Country
6.1.2.2 North America Injectable Market by Country
6.1.3 North America Muscle Relaxant Drugs Market by Distribution Channel
6.1.3.1 North America Hospital Pharmacy Market by Country
6.1.3.2 North America Retail Pharmacy Market by Country
6.1.3.3 North America Online Pharmacies Market by Country
6.1.4 North America Muscle Relaxant Drugs Market by Country
6.1.4.1 US Muscle Relaxant Drugs Market
6.1.4.1.1 US Muscle Relaxant Drugs Market by Drug Type
6.1.4.1.2 US Muscle Relaxant Drugs Market by Route of Administration
6.1.4.1.3 US Muscle Relaxant Drugs Market by Distribution Channel
6.1.4.2 Canada Muscle Relaxant Drugs Market
6.1.4.2.1 Canada Muscle Relaxant Drugs Market by Drug Type
6.1.4.2.2 Canada Muscle Relaxant Drugs Market by Route of Administration
6.1.4.2.3 Canada Muscle Relaxant Drugs Market by Distribution Channel
6.1.4.3 Mexico Muscle Relaxant Drugs Market
6.1.4.3.1 Mexico Muscle Relaxant Drugs Market by Drug Type
6.1.4.3.2 Mexico Muscle Relaxant Drugs Market by Route of Administration
6.1.4.3.3 Mexico Muscle Relaxant Drugs Market by Distribution Channel
6.1.4.4 Rest of North America Muscle Relaxant Drugs Market
6.1.4.4.1 Rest of North America Muscle Relaxant Drugs Market by Drug Type
6.1.4.4.2 Rest of North America Muscle Relaxant Drugs Market by Route of Administration
6.1.4.4.3 Rest of North America Muscle Relaxant Drugs Market by Distribution Channel
6.2 Europe Muscle Relaxant Drugs Market
6.2.1 Europe Muscle Relaxant Drugs Market by Drug Type
6.2.1.1 Europe Skeletal Market by Country
6.2.1.2 Europe Neuromuscular Blocking Agents Market by Country
6.2.1.3 Europe Facial Muscle Relaxant Drugs Market by Country
6.2.2 Europe Muscle Relaxant Drugs Market by Route of Administration
6.2.2.1 Europe Oral Market by Country
6.2.2.2 Europe Injectable Market by Country
6.2.3 Europe Muscle Relaxant Drugs Market by Distribution Channel
6.2.3.1 Europe Hospital Pharmacy Market by Country
6.2.3.2 Europe Retail Pharmacy Market by Country
6.2.3.3 Europe Online Pharmacies Market by Country
6.2.4 Europe Muscle Relaxant Drugs Market by Country
6.2.4.1 Germany Muscle Relaxant Drugs Market
6.2.4.1.1 Germany Muscle Relaxant Drugs Market by Drug Type
6.2.4.1.2 Germany Muscle Relaxant Drugs Market by Route of Administration
6.2.4.1.3 Germany Muscle Relaxant Drugs Market by Distribution Channel
6.2.4.2 UK Muscle Relaxant Drugs Market
6.2.4.2.1 UK Muscle Relaxant Drugs Market by Drug Type
6.2.4.2.2 UK Muscle Relaxant Drugs Market by Route of Administration
6.2.4.2.3 UK Muscle Relaxant Drugs Market by Distribution Channel
6.2.4.3 France Muscle Relaxant Drugs Market
6.2.4.3.1 France Muscle Relaxant Drugs Market by Drug Type
6.2.4.3.2 France Muscle Relaxant Drugs Market by Route of Administration
6.2.4.3.3 France Muscle Relaxant Drugs Market by Distribution Channel
6.2.4.4 Russia Muscle Relaxant Drugs Market
6.2.4.4.1 Russia Muscle Relaxant Drugs Market by Drug Type
6.2.4.4.2 Russia Muscle Relaxant Drugs Market by Route of Administration
6.2.4.4.3 Russia Muscle Relaxant Drugs Market by Distribution Channel
6.2.4.5 Spain Muscle Relaxant Drugs Market
6.2.4.5.1 Spain Muscle Relaxant Drugs Market by Drug Type
6.2.4.5.2 Spain Muscle Relaxant Drugs Market by Route of Administration
6.2.4.5.3 Spain Muscle Relaxant Drugs Market by Distribution Channel
6.2.4.6 Italy Muscle Relaxant Drugs Market
6.2.4.6.1 Italy Muscle Relaxant Drugs Market by Drug Type
6.2.4.6.2 Italy Muscle Relaxant Drugs Market by Route of Administration
6.2.4.6.3 Italy Muscle Relaxant Drugs Market by Distribution Channel
6.2.4.7 Rest of Europe Muscle Relaxant Drugs Market
6.2.4.7.1 Rest of Europe Muscle Relaxant Drugs Market by Drug Type
6.2.4.7.2 Rest of Europe Muscle Relaxant Drugs Market by Route of Administration
6.2.4.7.3 Rest of Europe Muscle Relaxant Drugs Market by Distribution Channel
6.3 Asia Pacific Muscle Relaxant Drugs Market
6.3.1 Asia Pacific Muscle Relaxant Drugs Market by Drug Type
6.3.1.1 Asia Pacific Skeletal Market by Country
6.3.1.2 Asia Pacific Neuromuscular Blocking Agents Market by Country
6.3.1.3 Asia Pacific Facial Muscle Relaxant Drugs Market by Country
6.3.2 Asia Pacific Muscle Relaxant Drugs Market by Route of Administration
6.3.2.1 Asia Pacific Oral Market by Country
6.3.2.2 Asia Pacific Injectable Market by Country
6.3.3 Asia Pacific Muscle Relaxant Drugs Market by Distribution Channel
6.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
6.3.3.2 Asia Pacific Retail Pharmacy Market by Country
6.3.3.3 Asia Pacific Online Pharmacies Market by Country
6.3.4 Asia Pacific Muscle Relaxant Drugs Market by Country
6.3.4.1 China Muscle Relaxant Drugs Market
6.3.4.1.1 China Muscle Relaxant Drugs Market by Drug Type
6.3.4.1.2 China Muscle Relaxant Drugs Market by Route of Administration
6.3.4.1.3 China Muscle Relaxant Drugs Market by Distribution Channel
6.3.4.2 Japan Muscle Relaxant Drugs Market
6.3.4.2.1 Japan Muscle Relaxant Drugs Market by Drug Type
6.3.4.2.2 Japan Muscle Relaxant Drugs Market by Route of Administration
6.3.4.2.3 Japan Muscle Relaxant Drugs Market by Distribution Channel
6.3.4.3 India Muscle Relaxant Drugs Market
6.3.4.3.1 India Muscle Relaxant Drugs Market by Drug Type
6.3.4.3.2 India Muscle Relaxant Drugs Market by Route of Administration
6.3.4.3.3 India Muscle Relaxant Drugs Market by Distribution Channel
6.3.4.4 South Korea Muscle Relaxant Drugs Market
6.3.4.4.1 South Korea Muscle Relaxant Drugs Market by Drug Type
6.3.4.4.2 South Korea Muscle Relaxant Drugs Market by Route of Administration
6.3.4.4.3 South Korea Muscle Relaxant Drugs Market by Distribution Channel
6.3.4.5 Singapore Muscle Relaxant Drugs Market
6.3.4.5.1 Singapore Muscle Relaxant Drugs Market by Drug Type
6.3.4.5.2 Singapore Muscle Relaxant Drugs Market by Route of Administration
6.3.4.5.3 Singapore Muscle Relaxant Drugs Market by Distribution Channel
6.3.4.6 Malaysia Muscle Relaxant Drugs Market
6.3.4.6.1 Malaysia Muscle Relaxant Drugs Market by Drug Type
6.3.4.6.2 Malaysia Muscle Relaxant Drugs Market by Route of Administration
6.3.4.6.3 Malaysia Muscle Relaxant Drugs Market by Distribution Channel
6.3.4.7 Rest of Asia Pacific Muscle Relaxant Drugs Market
6.3.4.7.1 Rest of Asia Pacific Muscle Relaxant Drugs Market by Drug Type
6.3.4.7.2 Rest of Asia Pacific Muscle Relaxant Drugs Market by Route of Administration
6.3.4.7.3 Rest of Asia Pacific Muscle Relaxant Drugs Market by Distribution Channel
6.4 LAMEA Muscle Relaxant Drugs Market
6.4.1 LAMEA Muscle Relaxant Drugs Market by Drug Type
6.4.1.1 LAMEA Skeletal Market by Country
6.4.1.2 LAMEA Neuromuscular Blocking Agents Market by Country
6.4.1.3 LAMEA Facial Muscle Relaxant Drugs Market by Country
6.4.2 LAMEA Muscle Relaxant Drugs Market by Route of Administration
6.4.2.1 LAMEA Oral Market by Country
6.4.2.2 LAMEA Injectable Market by Country
6.4.3 LAMEA Muscle Relaxant Drugs Market by Distribution Channel
6.4.3.1 LAMEA Hospital Pharmacy Market by Country
6.4.3.2 LAMEA Retail Pharmacy Market by Country
6.4.3.3 LAMEA Online Pharmacies Market by Country
6.4.4 LAMEA Muscle Relaxant Drugs Market by Country
6.4.4.1 Brazil Muscle Relaxant Drugs Market
6.4.4.1.1 Brazil Muscle Relaxant Drugs Market by Drug Type
6.4.4.1.2 Brazil Muscle Relaxant Drugs Market by Route of Administration
6.4.4.1.3 Brazil Muscle Relaxant Drugs Market by Distribution Channel
6.4.4.2 Argentina Muscle Relaxant Drugs Market
6.4.4.2.1 Argentina Muscle Relaxant Drugs Market by Drug Type
6.4.4.2.2 Argentina Muscle Relaxant Drugs Market by Route of Administration
6.4.4.2.3 Argentina Muscle Relaxant Drugs Market by Distribution Channel
6.4.4.3 UAE Muscle Relaxant Drugs Market
6.4.4.3.1 UAE Muscle Relaxant Drugs Market by Drug Type
6.4.4.3.2 UAE Muscle Relaxant Drugs Market by Route of Administration
6.4.4.3.3 UAE Muscle Relaxant Drugs Market by Distribution Channel
6.4.4.4 Saudi Arabia Muscle Relaxant Drugs Market
6.4.4.4.1 Saudi Arabia Muscle Relaxant Drugs Market by Drug Type
6.4.4.4.2 Saudi Arabia Muscle Relaxant Drugs Market by Route of Administration
6.4.4.4.3 Saudi Arabia Muscle Relaxant Drugs Market by Distribution Channel
6.4.4.5 South Africa Muscle Relaxant Drugs Market
6.4.4.5.1 South Africa Muscle Relaxant Drugs Market by Drug Type
6.4.4.5.2 South Africa Muscle Relaxant Drugs Market by Route of Administration
6.4.4.5.3 South Africa Muscle Relaxant Drugs Market by Distribution Channel
6.4.4.6 Nigeria Muscle Relaxant Drugs Market
6.4.4.6.1 Nigeria Muscle Relaxant Drugs Market by Drug Type
6.4.4.6.2 Nigeria Muscle Relaxant Drugs Market by Route of Administration
6.4.4.6.3 Nigeria Muscle Relaxant Drugs Market by Distribution Channel
6.4.4.7 Rest of LAMEA Muscle Relaxant Drugs Market
6.4.4.7.1 Rest of LAMEA Muscle Relaxant Drugs Market by Drug Type
6.4.4.7.2 Rest of LAMEA Muscle Relaxant Drugs Market by Route of Administration
6.4.4.7.3 Rest of LAMEA Muscle Relaxant Drugs Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Amneal Pharmaceuticals, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent Strategies and Developments
7.1.5.1 Acquisition and Mergers
7.2 Ipsen Pharma Biotech SAS
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent Strategies and Developments
7.2.5.1 Product Launches and Product Expansions
7.3 Merz Pharma GmbH & Co. KGaA
7.3.1 Company Overview
7.4 Mallinckrodt PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 Eisai Co., Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Endo International PLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.8 Vertical Pharmaceuticals, LLC
7.8.1 Company Overview
7.9 SteriMax Inc.
7.9.1 Company Overview
7.10. Metacel Pharmaceuticals, LLC.
7.10.1 Company Overview

Companies Mentioned

  • Amneal Pharmaceuticals, Inc.
  • Ipsen Pharma Biotech SAS
  • Merz Pharma GmbH & Co. KGaA
  • Mallinckrodt PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Eisai Co., Ltd.
  • Endo International PLC
  • Vertical Pharmaceuticals, LLC
  • SteriMax Inc.
  • Metacel Pharmaceuticals, LLC

Methodology

Loading
LOADING...

Related Topics

Related Reports

Muscle Relaxant Drugs Global Market Report 2024 - Product Image

Muscle Relaxant Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Muscle Relaxants Drug Market by Drug, Distribution - Global Forecast 2025-2030 - Product Image

Muscle Relaxants Drug Market by Drug, Distribution - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Muscle Relaxant Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Muscle Relaxant Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
2024 Global Forecast for Skeletal Muscle Relaxants (2025-2030 Outlook) - Manufacturing & Markets Report - Product Image

2024 Global Forecast for Skeletal Muscle Relaxants (2025-2030 Outlook) - Manufacturing & Markets Report

  • Report
  • 132 Pages
  • Global
From
Degenerative Disc Disease Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drugs, By End Use (Hospitals, Clinics, and Others), By Treatment Type, By Regional Outlook and Forecast, 2024 - 2031 - Product Image

Degenerative Disc Disease Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, and Injectable), By Drugs, By End Use (Hospitals, Clinics, and Others), By Treatment Type, By Regional Outlook and Forecast, 2024 - 2031

  • Report
  • 300 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.